The researchers started from a deceptively simple premise. Acetylation, a post-translational modification in which acetyl groups are added to proteins, is known to govern vascular development, inflammatory responses, and cellular behavior in disorders ranging from atherosclerosis to thoracic aortic aneurysms. Yet its role in moyamoya disease had barely been explored. To fill that gap, the team mined publicly available transcriptomic datasets from the Gene Expression Omnibus, combining microarray data from 32 middle cerebral artery wall samples and eight superficial temporal artery samples, then intersected the resulting differentially expressed genes with a predefined set of 73 acetylation-regulatory genes.

That intersection yielded 19 acetylation-related differentially expressed genes, including BAZ1B, BRD3, and BRD7. Using consensus clustering, a statistical method that repeatedly reassigns samples to groups to test how stably they cohere, the researchers found that moyamoya disease splits most cleanly into two molecular subtypes when classified by the expression of these acetylation-related genes. The two clusters, labeled C1 and C2, were not merely statistical artifacts. Transcriptome-wide differential expression between them revealed 472 genes that varied by subtype, and pathway enrichment analysis showed that each cluster carried a distinct biological signature involving hypoxic injury, vascular remodeling, angiogenesis, and immune-inflammatory activity.

From this molecular heterogeneity, five candidate genes rose to the top: STK39, NEO1, PKNOX1, GOLT1B, and MTMR12. Each was expressed at lower levels in moyamoya disease than in non-moyamoya surgical controls, though the authors are careful to note that none met the transcriptome-wide false discovery rate threshold in the primary comparison. STK39 did cross that threshold when moyamoya samples were compared specifically with epilepsy controls, giving the team an exploratory but meaningful signal to pursue. STK39 encodes STE20-related proline/alanine-rich kinase, or SPAK, a downstream effector of WNK kinases that regulates cation-chloride cotransport and cellular ion homeostasis, and has previously been implicated in hypertension, Parkinson’s disease susceptibility, and autism risk.

To test whether these candidates were biologically relevant rather than statistical curiosities, the researchers measured serum concentrations of STK39 and MTMR12 by ELISA in a small preliminary cohort of three moyamoya patients and three healthy controls. Both proteins were significantly decreased in the patient group, with P values of 0.0140 and 0.0055 respectively. The authors stress that this sample size is far too small to constitute independent validation, but the concordance between transcriptomic and serum findings provided enough preliminary support to justify moving STK39 into the laboratory for functional testing.

That functional work took place in human brain microvascular endothelial cells, the very cells that line the cerebral microvasculature and bear the brunt of moyamoya pathology. Using siRNA-mediated knockdown, the researchers silenced STK39 and exposed the cells to either normal oxygen levels or hypoxic conditions mimicking the chronic cerebral hypoperfusion that defines the disease. The results were striking. Under hypoxia, STK39 knockdown promoted endothelial cell migration while simultaneously inhibiting proliferation, a combination that hints at the abnormal vascular remodeling seen in moyamoya disease, where vessels proliferate pathologically rather than functionally.

The molecular consequences of losing STK39 were equally revealing. Knockdown increased the expression of HIF-1α, the master transcriptional regulator of the hypoxic response, along with phosphorylated STAT3, cleaved Caspase-3, IL-6, CCL2, and VCAM-1. Together, these markers paint a picture of endothelial cells caught in a state of inflammatory activation and apoptotic stress, precisely the kind of endothelial dysfunction that could drive the intimal hyperplasia and vascular occlusion characteristic of moyamoya disease. The STAT3 pathway in particular is well established as a driver of angiogenesis and vascular smooth muscle cell phenotype switching, and the immune infiltration analysis showed that monocytes and macrophages differed significantly between the two molecular subtypes, linking the kinase to a broader inflammatory ecosystem.

Perhaps the most intriguing therapeutic signal came from trichostatin A, a histone deacetylase inhibitor added to the hypoxic, STK39-deficient cells as an exploratory pharmacological intervention. TSA partially reversed the enhanced migration, restored some of the lost proliferation, reduced the global lysine acetylation signal that had been elevated by the treatment, and dampened the expression of HIF-1α, phosphorylated STAT3, cleaved Caspase-3, IL-6, CCL2, and VCAM-1. While the authors emphasize that this does not establish acetylation-dependent regulation of STK39 itself, the partial rescue suggests that the acetylation machinery sits somewhere in the same pathological circuit and could represent a target for future mechanistic studies.

The study is candid about its limitations. The transcriptomic analysis relied on small, heterogeneous surgical control groups that included patients with intracranial aneurysms and epilepsy rather than perfectly matched healthy vessels. The serum validation involved only six participants. The in vitro hypoxia model represents an acute and simplified reduction in oxygen availability that cannot reproduce the chronic, fluctuating hemodynamic environment, altered shear stress, or the complex interactions among endothelial cells, smooth muscle cells, and immune cells that define moyamoya vascular pathology. The molecular clusters were defined from gene expression rather than direct measurements of protein acetylation, so they should not be read as confirmed high- and low-acetylation states.

Even with those caveats, the findings add a genuinely new dimension to moyamoya research. The disease has traditionally been framed through the lens of RNF213, the best-established susceptibility gene, and through vascular smooth muscle cell abnormalities. This study suggests that the molecular pathology extends beyond a single genetic determinant into a network of post-translational modification regulators, immune cell interactions, and hypoxia-driven endothelial responses. STK39, sitting at the intersection of ion homeostasis, blood pressure regulation, nitric oxide signaling, and now endothelial inflammatory activation, emerges as a candidate gene worth pursuing in larger, independent cohorts. If future work confirms its role and clarifies its relationship with acetylation pathways, it could open a path toward targeted interventions for a disease whose effective diagnosis and treatment remain limited precisely because its pathogenesis has stayed hidden for so long.

Subject of Research: Moyamoya disease

Article Title: STK39 is associated with endothelial dysfunction and inflammatory activation under hypoxic conditions in moyamoya disease

Article References: STK39 is associated with endothelial dysfunction and inflammatory activation under hypoxic conditions in moyamoya disease. (n.d.). https://doi.org/10.3389/fnhum.2026.1854099

Image Credits: AI Generated

DOI: 10.3389/fnhum.2026.1854099

Keywords: moyamoya disease, STK39, acetylation, endothelial dysfunction, hypoxia, inflammation, cerebrovascular disease, STAT3, HIF-1α, trichostatin A, associated, endothelial

The heart is an organ with an unforgiving relationship to its blood supply. Cardiac muscle works continuously and demands a constant delivery of oxygen, which means the coronary vasculature must grow in careful proportion to the muscle it serves. Too little vessel growth starves the tissue; too much creates a disorganized, inefficient network. During development, and again after injury, the heart must therefore solve a problem that engineers would recognize immediately: building the right amount of blood vessel, and knowing precisely when to stop. The new study suggests that the zebrafish heart solves this problem with a dedicated cellular control system, one that had gone unnoticed until now because it only becomes prominent under specific conditions of growth and repair.

The research is rooted in a question that has animated the field for years. Zebrafish possess a remarkable ability that mammals largely lack: after significant injury to the heart, they can regenerate the damaged muscle almost completely, restoring function rather than forming a permanent scar. Understanding how they accomplish this has become a major strategy for identifying the regenerative programs that might, in principle, be reawakened in human patients. Dr. Jingli Cao, associate professor of cell and developmental biology at Weill Cornell Medicine and a member of its Cardiovascular Research Institute, has spent much of his career tracing this process. As a postdoctoral fellow at Duke University, he determined that the epicardium, the thin layer of cells that envelops the heart, provides both the signals and the cells needed to regenerate heart tissue in zebrafish.

The epicardium has long been viewed as more than passive packaging. In response to injury, it activates a specific population of progenitor cells that give rise to the various cell types involved in regenerating heart muscle and coronary blood vessels. But a deeper puzzle remained: what directs these precursor cells to specialize into one fate or another? To answer it, Dr. Cao’s team, including graduate student Björn Perder and postdoctoral fellow Dr. Yu Xia, catalogued the genes that switch on in these cells when the heart is injured. Among the activated genes they identified a master regulator called scxa, a transcription factor that steers a subset of epicardial progenitor cells toward a fate that had never been characterized before.

That fate turned out to be a novel perivascular cell type. Once specified by scxa, these cells migrate to the coronary vessels and surround them, taking up a position that immediately suggested a regulatory role. Perivascular cells in general are known to modulate vessel stability, maturation, and remodeling, so the location of the new cell type was a strong clue. The team found that these cells express a particular type of collagen, and that this collagen does more than provide structural support. The cells process the collagen molecule to release a small protein fragment, a derived signal that ultimately curbs further vessel expansion. In other words, the very cells that accompany the growing vasculature carry within them the molecular message that tells the network when enough is enough.

Dr. Cao framed the significance of this arrangement in practical terms. During development, or when the heart is damaged, the organism needs to build the right amount of blood vessel, and it needs to know when to stop, he noted. The newly discovered system provides that layer of control. This kind of negative feedback is a recurring theme in biology, but identifying the specific cell type and the specific signaling molecule responsible in the heart gives researchers a concrete handle on a process that has been difficult to study. It also suggests that disorders of vascular growth in the heart, whether insufficient vessel formation after injury or excessive, disorganized growth, might be traceable to failures of this regulatory circuit.

Perhaps the most intriguing aspect of the study is what it reveals about timing. The researchers had previously shown that when regions of the heart experience low oxygen levels, a condition known as hypoxia, signals from the epicardium coordinate the growth of heart muscle and coronary vessels so that the two develop in step with each other. The new findings illuminate a plausible mechanism for how this coordination happens. Low oxygen appears to act as an environmental cue that temporarily activates scxa, which in turn directs a subset of epicardial progenitors toward the perivascular fate. These cells then surround the coronary vessels and may help regulate their development and remodeling. Hypoxia, in this model, is not merely a stress signal but an instruction: it tells the epicardium that the tissue is outpacing its blood supply and that vascular support cells are needed now.

This oxygen-sensing logic has an elegant developmental rationale. As heart muscle proliferates, the growing tissue inevitably pushes local oxygen levels down, because diffusion cannot keep pace with expansion. By using hypoxia as the trigger for scxa activation, the heart ensures that vessel-supporting cells are generated exactly where and when the muscle is growing fastest. The same mechanism likely operates after injury, when the damaged tissue becomes hypoxic and the epicardium mounts its regenerative response. If the system works as the study suggests, the perivascular cells and their collagen-derived braking signal would form a self-correcting loop: hypoxia recruits the cells, the cells support vessel growth, and the vessels restore oxygen delivery, at which point the signal to expand fades.

The translational implications are considerable, though the researchers are careful about the distance between zebrafish and humans. Humans do carry a related gene, SCX, but no one yet knows whether human epicardial cells use it in the same way as their zebrafish counterparts. There is a cautionary wrinkle: after an injury such as a heart attack in mammals, SCX is switched on in cardiac fibroblasts, the cells that promote scar tissue formation. In mammals, then, the same regulatory gene appears to be associated with fibrosis rather than regeneration. Dr. Cao suggests that in the future it may be possible to use SCX to reactivate human epicardial cells and steer them toward generating the cells and signals that promote heart regeneration, redirecting the gene’s activity away from scarring and toward repair.

Toward that end, Dr. Cao’s laboratory is working with cultured human epicardial cells and cardiac organoids, laboratory-grown miniature tissue models, to develop ways of using activated cells to repair damaged regions of the heart. The vision is a kind of biological bandage: a living material that could be applied to an injured site and induce controlled growth of both heart muscle and vessels, rebuilding the tissue in a coordinated fashion rather than leaving a non-contractile scar. Dr. Cao is quick to temper expectations, noting that he does not believe a single magic factor controls regeneration. But, as he put it, the team has discovered one more factor, one more mechanism that could eventually contribute to turning on epicardial cells and repairing human hearts. The work was supported by the New York State Stem Cell Science program, the Louis and Rachel Rudin Foundation, the Belgian American Educational Foundation, the American Heart Association, and the National Institutes of Health, reflecting the broad institutional bet that the zebrafish heart still has many secrets worth stealing.

Subject of Research: Discovery of a novel scxa-specified perivascular cell type that regulates coronary vascular development in the regenerating zebrafish heart

Article Title: Newly discovered cell helps shape blood vessel growth in the heart

Article References: Newly discovered cell helps shape blood vessel growth in the heart. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: zebrafish, heart regeneration, epicardium, perivascular cells, coronary vessels, scxa, hypoxia, collagen, Weill Cornell Medicine, Nature Communications, cardiac progenitor cells, vascular development

The research, led by Audra R. Barnes-Lanier and John C. Chappell at Virginia Tech’s Fralin Biomedical Research Institute, provides the first detailed look at how these soluble receptor variants behave in the developing placenta of both mice and humans. The team documented progressively increasing pericyte coverage of fetoplacental capillaries across gestation, confirmed that placental pericytes display the same phenotypic diversity seen in the brain, heart, and lungs, and then demonstrated that soluble PDGFRβ isoforms are produced at both the RNA and protein levels throughout pregnancy. Most intriguingly, their functional experiments suggest these soluble fragments can modulate the very signaling pathway that recruits pericytes to nascent blood vessels in the first place.

Pericytes are specialized mural cells that wrap around capillaries, reinforcing vessel integrity and coordinating vascular maturation through intimate communication with endothelial cells. The primary chemical conversation between these two cell types runs through platelet-derived growth factor-BB, or PDGF-BB, which endothelial cells display on their surfaces to attract PDGFRβ-bearing pericytes. Decades of genetic work have shown that this pathway must be calibrated with extraordinary precision. Too little PDGF-BB signaling and pericytes abandon the vessel wall, leaving fragile, leaky, hemorrhage-prone capillaries; in mice, loss of PDGF-B or PDGFRβ produces placental abnormalities among a constellation of developmental defects. Too much signaling, on the other hand, drives pericyte hyperproliferation, vascular malformations, and fibrosis, as seen in patients carrying activating PDGFRB mutations.

Soluble receptor isoforms have emerged as one way biology walks this tightrope. Across the receptor tyrosine kinase family, truncated receptor variants generated by alternative mRNA splicing or proteolytic cleavage can act as decoys, sponging up ligand or interfering with full-length receptor activity. The most celebrated example is soluble Flt-1, or sFlt-1, which restrains VEGF-A signaling during vascular sprouting and, when misregulated in the placenta, becomes a central driver of preeclampsia. Until recently, however, soluble PDGFRβ was largely viewed as a degradation product, a biomarker of pericyte damage detected in the aging and diseased brain rather than a molecule with a job of its own. That view began to shift when the Chappell laboratory and collaborators showed that alternatively spliced sPDGFRβ transcripts and proteins are produced under entirely normal developmental conditions.

In the new work, the team turned to the placenta to ask whether these variants might matter during pregnancy. Examining mouse placentas at embryonic days 9.5, 14.5, and 18.5, they found that NG2-positive pericytes appear alongside the earliest vasculogenic structures and progressively invest the expanding capillary network, matching the pace of endothelial growth. Transcriptional analysis confirmed rising expression of pericyte genes including Cspg4, Acta2, and full-length Pdgfrβ across gestation, alongside coordinated changes in the Vegfa, Flt-1, and Pdgfb pathways. Western blotting revealed parallel increases in both the full-length receptor, at roughly 160 kilodaltons, and truncated soluble isoforms. Human placenta samples from uncomplicated full-term pregnancies told the same story, with full-length PDGFRβ and a shorter, soluble variant present in every quadrant examined, though with notable regional heterogeneity across the organ.

To dissect how sPDGFRβ is regulated and what it does, the researchers exploited a murine trophoblast and embryonic stem cell differentiation model, or TESC model, that recapitulates key features of early placental vascular development. As these stem cells differentiated, they formed primitive vascular networks containing fluorescently labeled endothelial cells and pericyte progenitors, while also generating trophoblast lineage cells marked by cytokeratins and the tight junction protein ZO-1, mirroring the cellular constituents of the developing placenta. Within this system, soluble PDGFRβ proteins appeared and accumulated alongside full-length receptor during vessel formation, accompanied by transcripts encoding intron-4 and intron-10 truncation variants previously characterized in the healthy brain.

The regulation experiments yielded two unexpected findings. First, blocking the metalloprotease ADAM10, long implicated in shedding soluble PDGFRβ from damaged pericytes, had no effect on soluble receptor levels during early vessel formation, and instead increased full-length receptor abundance, suggesting that in the developmental context, alternative mRNA splicing rather than proteolytic cleavage is the dominant source. Second, exogenous growth factors failed to boost sPDGFRβ production; adding VEGF-A or PDGF-BB to the cultures actually lowered soluble isoform levels slightly, while PDGF-BB significantly reduced full-length receptor, consistent with ligand-induced receptor internalization and degradation. Hypoxia, however, proved to be a powerful stimulus, driving a robust and sustained increase in soluble PDGFRβ protein after just 12 hours at 3 percent oxygen, and again at 48 hours, while full-length receptor remained unchanged.

That hypoxic sensitivity may be the key to the whole story, because low oxygen tension is a defining feature of early placentation and a hallmark of placental insufficiency. To test whether elevated sPDGFRβ could actually influence PDGF-BB signaling, the team added a soluble receptor mimetic, a peptide spanning the PDGF-BB ligand-binding domain, to their developing vascular networks. As expected, excess PDGF-BB alone reduced full-length PDGFRβ levels while increasing phosphorylation of the receptor at a key regulatory tyrosine residue. But when the mimetic was co-administered, both effects were attenuated, pulling receptor abundance and phosphorylation back toward baseline. The result supports a model in which soluble PDGFRβ acts as a negative feedback modulator, buffering PDGF-BB signaling against overshoot, particularly when hypoxia threatens to destabilize the system.

The implications reach well beyond basic vascular biology. Pericyte dysfunction at the maternal-fetal interface is increasingly implicated in preeclampsia, fetal growth restriction, and the abnormal, poorly perfused vessels that characterize placental insufficiency, conditions that also elevate sFlt-1 and disrupt maternal cardiovascular health. If sPDGFRβ proves to be similarly misregulated in pathological pregnancies, it could serve as both a biomarker for stratifying at-risk patients and a therapeutic target for stabilizing fetoplacental vascular maturation. The authors also point to broader questions about why pericytes diversify into contractile and non-contractile subtypes across organs, and how RNA-binding proteins and splicing factors orchestrate soluble receptor production. Follow-on studies are already planned to validate sPDGFRβ transcript and protein structures, screen disease databases for associations with placental dysfunction, and determine whether the same oxygen-sensitive feedback loop protects, or fails to protect, the fragile vasculature of pregnancies under stress.

The placenta offers an unusually instructive setting in which to study soluble receptor biology because its oxygen environment changes dramatically over the course of gestation. Early placentation occurs under relatively low oxygen tension, a physiological state that protects the developing embryo from oxidative damage while the fetoplacental circulation is still being assembled. The observation that hypoxia robustly increased soluble PDGFRβ production in the TESC model, without altering full-length receptor abundance, suggests that the placenta may naturally encounter conditions that favor soluble isoform generation precisely when vascular remodeling is most active. This oxygen-sensitive behavior distinguishes sPDGFRβ from many other signaling modulators whose expression is driven primarily by ligand availability.

The distinction between alternatively spliced and proteolytically shed soluble receptor variants carries practical consequences for future research. Shed receptor fragments released from damaged pericytes have historically been interpreted as passive markers of injury, whereas splice-derived isoforms represent deliberate gene products that can be regulated independently of cell death or membrane cleavage. The finding that ADAM10 inhibition did not reduce soluble receptor levels during early vessel formation, and instead raised full-length receptor abundance, implies that the developmental placenta relies on transcriptional mechanisms rather than ectodomain shedding. This matters therapeutically, because strategies targeting metalloprotease activity would be unlikely to influence a splicing-derived soluble pool, while interventions aimed at splicing factors or RNA-binding proteins might.

The TESC differentiation model itself deserves attention as a methodological advance. Placental tissue is difficult to obtain and study experimentally, particularly at early developmental stages, and animal models do not fully capture human trophoblast biology. A system in which trophoblast lineage cells, endothelial cells, and pericyte progenitors arise together and assemble vascular-like networks provides a tractable platform for testing how individual signaling components behave in a placental context. The demonstration that soluble PDGFRβ isoforms appear in this model at both transcript and protein levels, matching what is seen in native mouse and human tissue, strengthens confidence that the model reflects genuine developmental regulation rather than an artifact of cell culture.

Several questions remain open before these findings can be translated. The functional experiments relied on a mimetic peptide spanning the ligand-binding domain, so it is not yet certain that endogenously produced soluble isoforms exert identical effects in vivo. The precise stoichiometry between soluble receptor, PDGF-BB ligand, and membrane-bound PDGFRβ that produces meaningful modulation of signaling has not been defined. Whether soluble PDGFRβ sequesters ligand directly, competes for receptor binding, or acts through some other mechanism also remains to be resolved. Answering these questions will require genetic models in which soluble isoform production can be selectively manipulated, allowing investigators to separate the contributions of splicing-derived variants from the full-length receptor they appear to regulate.

Subject of Research: Regulation of PDGF-BB signaling in placental pericytes by soluble PDGFRβ isoforms during fetoplacental vascular development

Article Title: Regulation of PDGF-BB signaling in placental pericytes by soluble PDGFRβ isoforms: implications for fetoplacental vascular development

Article References: Barnes-Lanier, A. R., Duggan, E. C., Dunkenberger, R. A., Lessard, C. V., Cosma, C. C., Steele, C. R., Taylor, S. V., Darden, J. A., Whitham, M. D., Durica, A. R., & Chappell, J. C. (2026). Regulation of PDGF-BB signaling in placental pericytes by soluble PDGFRβ isoforms: implications for fetoplacental vascular development. Angiogenesis, 29(4), Article 67. https://doi.org/10.1007/s10456-026-10091-3

Image Credits: AI Generated

DOI: 10.1007/s10456-026-10091-3

Keywords: placenta, pericytes, PDGF-BB, PDGFRβ, soluble receptor, angiogenesis, fetal development, hypoxia, endothelial cells, preeclampsia, vascular development, alternative splicing